Potential Protection of Pre-Existent Antibodies to Human Coronavirus 229E on COVID-19 Severity

The causes of the broad spectrum of severity in COVID-19 are unknown. A protecting impact by humoral immunity from earlier infections by viruses of the SARS-CoV-2 household may clarify a light type of this illness. This examine aimed to deal with whether or not the presence of antibodies in opposition to human seasonal coronaviruses (HCoVs) may forestall extreme manifestations of COVID-19.
A cross-sectional examine was carried out in 165 members. The presence of pre-existent antibodies in opposition to the seasonal HCoV-OC43, HCoV-HKU1, HCoV-229E, and HCoV-NL63 have been detected. From all the seasonal HCoVs studied, it was solely discovered that being seropositive to HCoV-229E introduced an affiliation (p = 0.012) with creating delicate medical signs of COVID-19 or being asymptomatic.
Multinomial regression evaluation confirmed that being seropositive to HCoV-229E is related to delicate or reasonable medical signs for COVID-19. Statistical evaluation additionally confirmed that being feminine is related to being asymptomatic for SARS-CoV-2 an infection or creating delicate COVID-19.
A subgroup evaluation taking solely seropositive to HCoV-229E revealed that females usually tend to develop asymptomatic SARS-CoV-2 an infection (OR = 27.242, 95% CI 2.092-354.706, p = 0.012). Our outcomes recommend that earlier infections by HCoV-229E may forestall extra critical medical manifestations of COVID-19, however these should not the one variables that affect this occasion.

The comparative efficacy and security of anti-CD20 monoclonal antibodies for relapsing-remitting a number of sclerosis: A community meta-analysis

With the latest profitable concentrating on of B lymphocytes in sufferers with a number of sclerosis (MS), therapy with anti-CD20 monoclonal antibodies (mAbs) might characterize a promising managemental strategy, significantly for these with relapsing/remitting MS (RRMS).
A community meta-analysis was carried out based mostly on a complete search in Embase, PubMed, and the Cochrane Library to evaluate the comparative efficacy and security of at present obtainable anti-CD20 monoclonal antibodies (mAbs), together with rituximab, ocrelizumab, and ofatumumab, versus a standard comparator (interferon beta-1a [INFβ-1a]) in RRMS sufferers recruited in randomized medical trials (RCTs).
In a frequentist community meta-analytical mannequin, annualized relapse charges (ARRs) and security outcomes have been expressed as threat ratios (RRs), whereas relapse-free occasions have been expressed as odds ratios (ORs). Remedy rating was carried out utilizing P-scores. The knowledge of proof was appraised utilizing the GRADE strategy.
5 publications reported the outcomes of seven RCTs (3938 sufferers, 67.09% females). In comparison with INFβ-1a, ocrelizumab lowered the chance of ARR (RR = 0.56, 95% CI, 0.50-0.64), critical adversarial occasions (RR = 0.17, 95% CI, 0.09-0.30), and therapy discontinuation as a consequence of adversarial occasions (SAEs, RR = 0.60, 95% CI, 0.39-0.93), and it was related to larger odds of no relapses (OR = 2.47, 95% CI, 2.00-3.05).
Ocrelizumab ranked finest amongst all different remedies by way of lowering ARR and SAEs. The standard of proof was low for ocrelizumab, low to reasonable for rituximab, and excessive for ofatumumab. Additional large-sized, well-designed RCTs are wanted to corroborate the efficacy and security of ocrelizumab and different anti-CD20 mAbs in RRMS.

Fc Receptor Variants and Illness: A Essential Issue to Contemplate within the Antibody Therapeutics in Clinic

The fragment crystallizable (Fc) area of antibodies is answerable for their protecting perform and long-lasting serum half-life by way of Fc-mediated effector perform, transcytosis, and recycling by its interplay with Fc receptors (FcRs) expressed on varied immune leukocytes, epithelial, and endothelial cells. Due to this fact, the Fc-FcRs interplay is a management level of each endogenous and therapeutic antibody perform.
There are a variety of reported genetic variants of FcRs, which embrace polymorphisms in (i) extracellular area of FcRs, which change their affinities to Fc area of antibodies; (ii) each cytoplasmic and intracellular area, which alters the extent of sign transduction; and (iii) the promoter area of the FcRs gene, which impacts the expression degree of FcRs, thus being related to the pathogenesis of illness indications.
On this assessment, we firstly describe the correlation between the genetic variants of FcRs and immunological problems by particular person variations within the extent of FcRs-mediated laws. Secondly, we focus on the affect of the genetic variants of FcRs on the susceptibility to infectious ailments or most cancers within the perspective of FcRs-induced effector capabilities. General, we concluded that the genetic variants of FcRs are one of many key components within the design of antibody therapeutics as a consequence of their number of medical outcomes amongst people.
 Potential Protection of Pre-Existent Antibodies to Human Coronavirus 229E on COVID-19 Severity

SARS-CoV-2 Spike Protein-Directed Monoclonal Antibodies Could Ameliorate COVID-19 Issues in APECED Sufferers

Sufferers with the monogenic immune dysregulatory syndrome autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED), which is brought on by loss-of-function mutations within the autoimmune regulator (AIRE) gene, uniformly carry neutralizing autoantibodies directed in opposition to type-I interferons (IFNs) and lots of develop autoimmune pneumonitis, each of which place them at excessive threat for life-threatening COVID-19 pneumonia.
Bamlanivimab and etesevimab are monoclonal antibodies (mAbs) that focus on the SARS-CoV-2 spike protein and block entry of SARS-CoV-2 in host cells. Using bamlanivimab and etesevimab early throughout an infection was related to lowered COVID-19-associated hospitalization and dying in sufferers at excessive threat for progressing to extreme illness, which led the US Meals and Drug Administration to subject an emergency use authorization for his or her administration in non-hypoxemic, non-hospitalized high-risk sufferers.
Nevertheless, the protection and efficacy of those mAbs has not been evaluated in APECED sufferers. We enrolled two siblings with APECED on an IRB-approved protocol  and admitted them prophylactically on the NIH Medical Heart for analysis of mild-to-moderate COVID-19. We assessed the protection and medical results of early therapy with bamlanivimab and etesevimab.
The administration of bamlanivimab and etesevimab was effectively tolerated and was related to amelioration of COVID-19 signs and prevention of invasive ventilatory help, admission to the intensive care, and dying in each sufferers with out affecting the manufacturing of antibodies to the nucleocapsid protein of SARS-CoV-2.
If given early in the midst of COVID-19 an infection, bamlanivimab and etesevimab could also be useful in APECED and different high-risk sufferers with neutralizing autoantibodies directed in opposition to type-I IFNs.
 Potential Protection of Pre-Existent Antibodies to Human Coronavirus 229E on COVID-19 Severity

Case Report: Full Response of Main Large Hepatocellular Carcinoma to Anti-Programmed Demise Ligand-1 Antibody Following Development on Anti-Programmed Demise-1 Antibody

Hepatocellular carcinoma (HCC) is an aggressive liver tumor that happens as a consequence of persistent liver illness, and it has a excessive mortality charge and restricted therapy choices. Immune checkpoint inhibitors have been efficiently launched and utilized in most cancers remedy, amongst which inhibitors of programmed dying ligand-1 (PD-L1) and its receptor programmed death-1 (PD-1) are generally administered for HCC as mixture remedy, together with mixed anti-angiogenic and immunotherapy mixture remedy.
 Potential Protection of Pre-Existent Antibodies to Human Coronavirus 229E on COVID-19 Severity
We report a case of a main large HCC affected person with portal hepatic vein tumor thrombus who had a great response to atezolizumab together with bevacizumab, following development of illness on mixed immunotherapy with pembrolizumab and lenvatinib.

CD54 antibody

10R-6420 100 ug
EUR 120
Description: Mouse monoclonal CD54 antibody

CD54 Antibody

E10-31462 100ul
EUR 225
Description: Available in various conjugation types.

CD54 Antibody

E10-31463 100ul
EUR 225
Description: Available in various conjugation types.

CD54 Antibody

E90307 100ul
EUR 255
Description: Available in various conjugation types.

CD54 Antibody

E38PA9666 100ul
EUR 225
Description: Available in various conjugation types.

CD54 Antibody

E38PA9767 100ul
EUR 225
Description: Available in various conjugation types.

CD54 Antibody

E38PA1570 100ul
EUR 225
Description: Available in various conjugation types.

CD54 antibody

70R-13774 100 ug
EUR 519
Description: Affinity purified Rabbit polyclonal CD54 antibody

CD54 antibody

70R-49888 100 ul
EUR 286
Description: Purified Polyclonal CD54 antibody

CD54 antibody

70R-49889 100 ul
EUR 242
Description: Purified Polyclonal CD54 antibody

CD54 Antibody

GWB-5E5425 0.2 mg Ask for price

CD54 Antibody

GWB-223784 0.02 mg Ask for price

CD54 Antibody

GWB-Q00663 0.1 mg Ask for price

CD54 Antibody

GWB-835F6B 0.1 mg Ask for price

CD54 Antibody

GWB-913883 0.2 mg Ask for price

CD54 Antibody

GWB-A24F91 0.2 mg Ask for price

CD54 Antibody

GWB-677F3D 0.1 mg Ask for price

CD54, Antibody

GWB-F6E6A3 1 ml Ask for price

CD54 Antibody

GWB-B857DF 0.025 mg Ask for price

CD54 Antibody

GWB-D7BAD5 2 ml Ask for price

CD54 Antibody

GWB-DE7C67 0.2 mg Ask for price

CD54 Antibody

abx228232-100g 100 µg
EUR 62.5

ICAM-1. CD54

GWB-53744A 0.05 mg Ask for price

ICAM-1/CD54

PR27037 2 ug
EUR 229.2

ICAM-1/CD54

PR27037-B each
EUR 184.5

CD54 Mouse mAb

E2222509 100ul
EUR 255
Description: Biotin-Conjugated, FITC-Conjugated , AF350 Conjugated , AF405M-Conjugated ,AF488-Conjugated, AF514-Conjugated ,AF532-Conjugated, AF555-Conjugated ,AF568-Conjugated , HRP-Conjugated, AF405S-Conjugated, AF405L-Conjugated , AF546-Conjugated, AF594-Conjugated , AF610-Conjugated, AF635-Conjugated , AF647-Conjugated , AF680-Conjugated , AF700-Conjugated , AF750-Conjugated , AF790-Conjugated , APC-Conjugated , PE-Conjugated , Cy3-Conjugated , Cy5-Conjugated , Cy5.5-Conjugated , Cy7-Conjugated Antibody

Mouse Human CD54

E2790160 100ul
EUR 225
Description: Available in various conjugation types.

CD54 Antibody (PE)

abx228235-100g 100 µg
EUR 50

CD54 Antibody (PE)

abx228424-100g 100 µg
EUR 100

sICAM-1/CD54 ELISA Kit| Rat CD54 ELISA Kit

EF018233 96 Tests
EUR 826.8

Rat CD54 Antibody

GWB-45DF27 0.2 mg Ask for price

Rat CD54 Antibody

GWB-48709A 0.1 mg Ask for price

CD54 Antibody (RPE)

GWB-FA6A1E 25 TESTS Ask for price

CD54 Antibody (RPE)

GWB-DDD77D 100 TESTS Ask for price

CD54 Antibody (APC)

abx228236-100g 100 µg
EUR 50

CD54 Antibody (APC)

abx228425-100g 100 µg
EUR 100

CD54 Antibody (FITC)

abx139538-100tests 100 tests
EUR 510

CD54 Antibody (FITC)

GWB-37D583 0.1 mg Ask for price

CD54 Antibody (FITC)

GWB-56D4AB 0.02 mg Ask for price

CD54 Antibody (FITC)

GWB-72853B 100 TESTS Ask for price

CD54 Antibody (FITC)

abx139538-100l 100 µl
EUR 350

CD54 Antibody (FITC)

abx139538-500l 500 µl Ask for price

CD54 Antibody (FITC)

abx228234-100g 100 µg
EUR 50

CD54 Antibody (FITC)

abx228423-100g 100 µg
EUR 93.75

CD54 (pT512) Antibody

20-abx009840
  • Ask for price
  • Ask for price
  • Ask for price
  • 100 ul
  • 200 ul
  • 30 ul

ICAM1/CD54 Antibody

35344 100ul
EUR 479

ICAM1/CD54 Antibody

35344-100ul 100ul
EUR 468

ICAM1 Antibody / CD54

RQ7001 100 ug
EUR 356.15
Description: CD54, also known as ICAM-1 and Intercellular adhesion molecule-1 (ICAM1) is a ligand for lymphocyte function-associated (LFA) antigens. ICAM-1 is an integral membrane protein, a member of the immunoglobulin superfamily, and a ligand for LFA-1, a beta 2 leukocyte integrin. This protein is the major human rhinovirus receptor. The ICAM1 gene is mapped to human chromosome 19. In humans, lymphocyte adhesion to cells is mediated by the protein heterodimer CD11a/CD18 (Leu-CAMa, LFA-1) and its ligand CD54 (ICAM-1).

ICAM1 Antibody / CD54

RQ7002 100 ug
EUR 356.15
Description: CD54, also known as ICAM-1 and Intercellular adhesion molecule-1 (ICAM1) is a ligand for lymphocyte function-associated (LFA) antigens. ICAM-1 is an integral membrane protein, a member of the immunoglobulin superfamily, and a ligand for LFA-1, a beta 2 leukocyte integrin. This protein is the major human rhinovirus receptor. The ICAM1 gene is mapped to human chromosome 19. In humans, lymphocyte adhesion to cells is mediated by the protein heterodimer CD11a/CD18 (Leu-CAMa, LFA-1) and its ligand CD54 (ICAM-1).

ICAM1 Antibody / CD54

RQ5121 100ul
EUR 356.15
Description: The ICAM1 gene encodes a cell surface glycoprotein which is typically expressed on endothelial cells and cells of the immune system. It binds to integrins of type CD11a / CD18, or CD11b / CD18 and is also exploited by Rhinovirus as a receptor. [RefSeq]

ICAM1 Antibody / CD54

V9194-100UG 100ug
EUR 424.15
Description: Recognizes an 85-115kDa protein (variation with cell type), identified as intercellular adhesion molecule (ICAM-1). It has 7 potential N-linked glycosylation sites. ICAM-1 is a single chain glycoprotein of Ig supergene family, present on unstimulated endothelial cells (EC) and on a variety of other cell types including activated fibroblasts, EC, macrophages, and lymphocytes. ICAM-1 mediates cell adhesion by binding to integrins CD11a/CD18 (leukocyte adhesion molecule, LFA-1) and to CD11b/CD18 (Mac-1). This interaction enhances antigen-specific T-cell activation. ICAM-1 also binds to CD43 and to Plasmodium falciparum infected RBCs. ICAM-1 may also be related to progression and metastasis of tumors.

ICAM1 Antibody / CD54

V9194-20UG 20ug
EUR 186.15
Description: Recognizes an 85-115kDa protein (variation with cell type), identified as intercellular adhesion molecule (ICAM-1). It has 7 potential N-linked glycosylation sites. ICAM-1 is a single chain glycoprotein of Ig supergene family, present on unstimulated endothelial cells (EC) and on a variety of other cell types including activated fibroblasts, EC, macrophages, and lymphocytes. ICAM-1 mediates cell adhesion by binding to integrins CD11a/CD18 (leukocyte adhesion molecule, LFA-1) and to CD11b/CD18 (Mac-1). This interaction enhances antigen-specific T-cell activation. ICAM-1 also binds to CD43 and to Plasmodium falciparum infected RBCs. ICAM-1 may also be related to progression and metastasis of tumors.

ICAM1 Antibody / CD54

V9194SAF-100UG 100ug
EUR 424.15
Description: Recognizes an 85-115kDa protein (variation with cell type), identified as intercellular adhesion molecule (ICAM-1). It has 7 potential N-linked glycosylation sites. ICAM-1 is a single chain glycoprotein of Ig supergene family, present on unstimulated endothelial cells (EC) and on a variety of other cell types including activated fibroblasts, EC, macrophages, and lymphocytes. ICAM-1 mediates cell adhesion by binding to integrins CD11a/CD18 (leukocyte adhesion molecule, LFA-1) and to CD11b/CD18 (Mac-1). This interaction enhances antigen-specific T-cell activation. ICAM-1 also binds to CD43 and to Plasmodium falciparum infected RBCs. ICAM-1 may also be related to progression and metastasis of tumors.

ICAM1 Antibody / CD54

V9197-100UG 100ug
EUR 424.15
Description: ICAM-1 is a single chain glycoprotein of Ig supergene family, present on unstimulated endothelial cells (EC) and on a variety of other cell types including activated fibroblasts, EC, macrophages, and lymphocytes.

ICAM1 Antibody / CD54

V9197-20UG 20ug
EUR 186.15
Description: ICAM-1 is a single chain glycoprotein of Ig supergene family, present on unstimulated endothelial cells (EC) and on a variety of other cell types including activated fibroblasts, EC, macrophages, and lymphocytes.

ICAM1 Antibody / CD54

V9197SAF-100UG 100ug
EUR 424.15
Description: ICAM-1 is a single chain glycoprotein of Ig supergene family, present on unstimulated endothelial cells (EC) and on a variety of other cell types including activated fibroblasts, EC, macrophages, and lymphocytes.

ICAM1 Antibody / CD54

V7851-100UG 100 ug
EUR 424.15
Description: Recognizes an 85-115kDa protein (variation with cell type), identified as intercellular adhesion molecule (ICAM-1). It has 7 potential N-linked glycosylation sites. ICAM-1 is a single chain glycoprotein of Ig supergene family, present on unstimulated endothelial cells (EC) and on a variety of other cell types including activated fibroblasts, EC, macrophages, and lymphocytes. ICAM-1 mediates cell adhesion by binding to integrins CD11a/CD18 (leukocyte adhesion molecule, LFA-1) and to CD11b/CD18 (Mac-1). This interaction enhances antigen-specific T-cell activation. ICAM-1 also binds to CD43 and to Plasmodium falciparum infected RBCs. ICAM-1 may also be related to progression and metastasis of tumors.

ICAM1 Antibody / CD54

V7851-20UG 20 ug
EUR 186.15
Description: Recognizes an 85-115kDa protein (variation with cell type), identified as intercellular adhesion molecule (ICAM-1). It has 7 potential N-linked glycosylation sites. ICAM-1 is a single chain glycoprotein of Ig supergene family, present on unstimulated endothelial cells (EC) and on a variety of other cell types including activated fibroblasts, EC, macrophages, and lymphocytes. ICAM-1 mediates cell adhesion by binding to integrins CD11a/CD18 (leukocyte adhesion molecule, LFA-1) and to CD11b/CD18 (Mac-1). This interaction enhances antigen-specific T-cell activation. ICAM-1 also binds to CD43 and to Plasmodium falciparum infected RBCs. ICAM-1 may also be related to progression and metastasis of tumors.

ICAM1 Antibody / CD54

V7851SAF-100UG 100 ug
EUR 424.15
Description: Recognizes an 85-115kDa protein (variation with cell type), identified as intercellular adhesion molecule (ICAM-1). It has 7 potential N-linked glycosylation sites. ICAM-1 is a single chain glycoprotein of Ig supergene family, present on unstimulated endothelial cells (EC) and on a variety of other cell types including activated fibroblasts, EC, macrophages, and lymphocytes. ICAM-1 mediates cell adhesion by binding to integrins CD11a/CD18 (leukocyte adhesion molecule, LFA-1) and to CD11b/CD18 (Mac-1). This interaction enhances antigen-specific T-cell activation. ICAM-1 also binds to CD43 and to Plasmodium falciparum infected RBCs. ICAM-1 may also be related to progression and metastasis of tumors.

ICAM1 Antibody / CD54

V2604-100UG 100 ug
EUR 424.15
Description: Recognizes an 85-115kDa protein (variation with cell type), identified as intercellular adhesion molecule (ICAM-1) (Workshop IV). It has 7 potential N-linked glycosylation sites. ICAM-1 is a single chain glycoprotein of Ig supergene family, present on unstimulated endothelial cells (EC) and on a variety of other cell types including activated fibroblasts, EC, macrophages, and lymphocytes. ICAM-1 mediates cell adhesion by binding to integrins CD11a/CD18 (leukocyte adhesion molecule, LFA-1) and to CD11b/CD18 (Mac-1). This interaction enhances antigen-specific T-cell activation. ICAM-1 also binds to CD43 and to Plasmodium falciparum infected RBCs. W-CAM-1 mAb blocks aggregation of cell lines mediated by the ICAM-1 and blocks homotypic binding of purified populations of activated T- and B-lymphocytes and also aggregation of mixed T- and B-cell blasts. It inhibits T-cell adhesion to normal human endothelial cells. Activation induced by cell-cell contact (mixed lymphocyte reaction, T-cell mediated B-cell activation) is significantly inhibited. This mAb blocks elements of both effector arms of immune system (cytotoxic cell function and Ig production).

ICAM1 Antibody / CD54

V2604-20UG 20 ug
EUR 186.15
Description: Recognizes an 85-115kDa protein (variation with cell type), identified as intercellular adhesion molecule (ICAM-1) (Workshop IV). It has 7 potential N-linked glycosylation sites. ICAM-1 is a single chain glycoprotein of Ig supergene family, present on unstimulated endothelial cells (EC) and on a variety of other cell types including activated fibroblasts, EC, macrophages, and lymphocytes. ICAM-1 mediates cell adhesion by binding to integrins CD11a/CD18 (leukocyte adhesion molecule, LFA-1) and to CD11b/CD18 (Mac-1). This interaction enhances antigen-specific T-cell activation. ICAM-1 also binds to CD43 and to Plasmodium falciparum infected RBCs. W-CAM-1 mAb blocks aggregation of cell lines mediated by the ICAM-1 and blocks homotypic binding of purified populations of activated T- and B-lymphocytes and also aggregation of mixed T- and B-cell blasts. It inhibits T-cell adhesion to normal human endothelial cells. Activation induced by cell-cell contact (mixed lymphocyte reaction, T-cell mediated B-cell activation) is significantly inhibited. This mAb blocks elements of both effector arms of immune system (cytotoxic cell function and Ig production).

ICAM1 Antibody / CD54

V2604IHC-7ML 7 ml
EUR 424.15
Description: Recognizes an 85-115kDa protein (variation with cell type), identified as intercellular adhesion molecule (ICAM-1) (Workshop IV). It has 7 potential N-linked glycosylation sites. ICAM-1 is a single chain glycoprotein of Ig supergene family, present on unstimulated endothelial cells (EC) and on a variety of other cell types including activated fibroblasts, EC, macrophages, and lymphocytes. ICAM-1 mediates cell adhesion by binding to integrins CD11a/CD18 (leukocyte adhesion molecule, LFA-1) and to CD11b/CD18 (Mac-1). This interaction enhances antigen-specific T-cell activation. ICAM-1 also binds to CD43 and to Plasmodium falciparum infected RBCs. W-CAM-1 mAb blocks aggregation of cell lines mediated by the ICAM-1 and blocks homotypic binding of purified populations of activated T- and B-lymphocytes and also aggregation of mixed T- and B-cell blasts. It inhibits T-cell adhesion to normal human endothelial cells. Activation induced by cell-cell contact (mixed lymphocyte reaction, T-cell mediated B-cell activation) is significantly inhibited. This mAb blocks elements of both effector arms of immune system (cytotoxic cell function and Ig production).

ICAM1 Antibody / CD54

V2604SAF-100UG 100 ug
EUR 424.15
Description: Recognizes an 85-115kDa protein (variation with cell type), identified as intercellular adhesion molecule (ICAM-1) (Workshop IV). It has 7 potential N-linked glycosylation sites. ICAM-1 is a single chain glycoprotein of Ig supergene family, present on unstimulated endothelial cells (EC) and on a variety of other cell types including activated fibroblasts, EC, macrophages, and lymphocytes. ICAM-1 mediates cell adhesion by binding to integrins CD11a/CD18 (leukocyte adhesion molecule, LFA-1) and to CD11b/CD18 (Mac-1). This interaction enhances antigen-specific T-cell activation. ICAM-1 also binds to CD43 and to Plasmodium falciparum infected RBCs. W-CAM-1 mAb blocks aggregation of cell lines mediated by the ICAM-1 and blocks homotypic binding of purified populations of activated T- and B-lymphocytes and also aggregation of mixed T- and B-cell blasts. It inhibits T-cell adhesion to normal human endothelial cells. Activation induced by cell-cell contact (mixed lymphocyte reaction, T-cell mediated B-cell activation) is significantly inhibited. This mAb blocks elements of both effector arms of immune system (cytotoxic cell function and Ig production).

ICAM1 Antibody / CD54

V2605-100UG 100 ug
EUR 424.15
Description: Recognizes an 85-115kDa protein (variation with cell type), identified as intercellular adhesion molecule (ICAM-1). It has 7 potential N-linked glycosylation sites. ICAM1 is a single chain glycoprotein of Ig supergene family, present on unstimulated endothelial cells (EC) and on a variety of other cell types including activated fibroblasts, EC, macrophages, and lymphocytes. ICAM1 mediates cell adhesion by binding to integrins CD11a/CD18 (leukocyte adhesion molecule, LFA-1) and to CD11b/CD18 (Mac-1). This interaction enhances antigen-specific T-cell activation. ICAM1 also binds to CD43 and to Plasmodium falciparum infected RBCs and may also be related to progression and metastasis of tumors.

ICAM1 Antibody / CD54

V2605-20UG 20 ug
EUR 186.15
Description: Recognizes an 85-115kDa protein (variation with cell type), identified as intercellular adhesion molecule (ICAM-1). It has 7 potential N-linked glycosylation sites. ICAM1 is a single chain glycoprotein of Ig supergene family, present on unstimulated endothelial cells (EC) and on a variety of other cell types including activated fibroblasts, EC, macrophages, and lymphocytes. ICAM1 mediates cell adhesion by binding to integrins CD11a/CD18 (leukocyte adhesion molecule, LFA-1) and to CD11b/CD18 (Mac-1). This interaction enhances antigen-specific T-cell activation. ICAM1 also binds to CD43 and to Plasmodium falciparum infected RBCs and may also be related to progression and metastasis of tumors.

ICAM1 Antibody / CD54

V2605SAF-100UG 100 ug
EUR 424.15
Description: Recognizes an 85-115kDa protein (variation with cell type), identified as intercellular adhesion molecule (ICAM-1). It has 7 potential N-linked glycosylation sites. ICAM1 is a single chain glycoprotein of Ig supergene family, present on unstimulated endothelial cells (EC) and on a variety of other cell types including activated fibroblasts, EC, macrophages, and lymphocytes. ICAM1 mediates cell adhesion by binding to integrins CD11a/CD18 (leukocyte adhesion molecule, LFA-1) and to CD11b/CD18 (Mac-1). This interaction enhances antigen-specific T-cell activation. ICAM1 also binds to CD43 and to Plasmodium falciparum infected RBCs and may also be related to progression and metastasis of tumors.

CD54 Antibody (AF488)

abx228242-100g 100 µg
EUR 62.5

CD54 Antibody (AF647)

abx228243-100g 100 µg
EUR 62.5

CD54 Antibody (Biotin)

abx139537-01mg 0.1 mg
EUR 510

CD54 antibody (biotin)

61R-1516 100 ug
EUR 420
Description: Mouse monoclonal CD54 antibody (biotin)

CD54 Antibody (Biotin)

GWB-15278C 0.1 mg Ask for price

CD54 Antibody (Biotin)

GWB-1D291D 0.02 mg Ask for price

CD54 Antibody (Biotin)

abx139537-100l 100 µl
EUR 350

CD54 Antibody (Biotin)

abx139537-500l 500 µl Ask for price

CD54 Antibody (Biotin)

abx228233-100g 100 µg
EUR 75

CD54 Blocking Peptide

20-abx062764
  • Ask for price
  • Ask for price
  • 1 mg
  • 5 mg

CD54 Polyclonal Antibody

E-AB-13130-120uL 120uL
EUR 240
Description: Unconjugated

CD54 Polyclonal Antibody

E-AB-13130-200uL 200uL
EUR 399
Description: Unconjugated

CD54 Polyclonal Antibody

E-AB-13130-20uL 20uL
EUR 73
Description: Unconjugated

CD54 Polyclonal Antibody

E-AB-13130-60uL 60uL
EUR 143
Description: Unconjugated

CD54 Polyclonal Antibody

E-AB-14711-120uL 120uL
EUR 240
Description: Unconjugated

CD54 Polyclonal Antibody

E-AB-14711-200uL 200uL
EUR 399
Description: Unconjugated

CD54 Polyclonal Antibody

E-AB-14711-20uL 20uL
EUR 73
Description: Unconjugated

CD54 Polyclonal Antibody

E-AB-14711-60uL 60uL
EUR 143
Description: Unconjugated

CD54 Polyclonal Antibody

E-AB-16322-120uL 120uL
EUR 240
Description: Unconjugated

CD54 Polyclonal Antibody

E-AB-16322-200uL 200uL
EUR 399
Description: Unconjugated

CD54 Polyclonal Antibody

E-AB-16322-20uL 20uL
EUR 73
Description: Unconjugated

CD54 Polyclonal Antibody

E-AB-16322-60uL 60uL
EUR 143
Description: Unconjugated

CD54 Polyclonal Antibody

E-AB-70046-120uL 120uL
EUR 260
Description: Unconjugated

CD54 Polyclonal Antibody

E-AB-70046-200uL 200uL
EUR 410
Description: Unconjugated

CD54 Polyclonal Antibody

E-AB-70046-60uL 60uL
EUR 160
Description: Unconjugated

CD54 Polyclonal Antibody

E-AB-70046-each each Ask for price
Description: Unconjugated

CD54 Polyclonal Antibody

E-AB-31758-120uL 120uL
EUR 240
Description: Unconjugated

CD54 Polyclonal Antibody

E-AB-31758-200uL 200uL
EUR 399
Description: Unconjugated

CD54 Polyclonal Antibody

E-AB-31758-20uL 20uL
EUR 73
Description: Unconjugated

CD54 Polyclonal Antibody

E-AB-31758-60uL 60uL
EUR 143
Description: Unconjugated

Anti-Hu CD54 PE

1P-429-T025 25 tests
EUR 121

Anti-Hu CD54 PE

1P-429-T100 100 tests
EUR 242

Anti-Hu CD54 PE

1P-228-T025 25 tests
EUR 121

Anti-Hu CD54 PE

1P-228-T100 100 tests
EUR 242

Anti-Hu CD54 APC

1A-429-T025 25 tests
EUR 121

Anti-Hu CD54 APC

1A-429-T100 100 tests
EUR 242

PE anti-rat CD54

E16FRP054-100U 100 μg
EUR 606.67
Description: Available in various conjugation types.

Anti-Hu CD54 FITC

1F-429-T025 25 tests
EUR 99

Anti-Hu CD54 FITC

1F-429-T100 100 tests
EUR 198

Anti-Ms CD54 FITC

1F-625-C100 0.1 mg
EUR 165

CD54(ICAM) Mouse mAb

27130 100ul
EUR 319

CD54(ICAM) Mouse mAb

27176 100ul
EUR 319

Mouse Human CD54 (PE)

E2790320 100ul
EUR 225
Description: Available in various conjugation types.

Human CD54 / ICAM-1

M850540096 1 unit
EUR 492.85

PE anti-mouse CD54

E16FMP054-050U 50 μg
EUR 390
Description: Available in various conjugation types.

PE anti-mouse CD54

E16FMP054-100U 100 μg
EUR 780
Description: Available in various conjugation types.

PE anti-mouse CD54

E16FMP054-200U 200 μg
EUR 1126.67
Description: Available in various conjugation types.

PE anti-human CD54

E16FHP054-025 25 tests
EUR 293.67
Description: Available in various conjugation types.

PE anti-human CD54

E16FHP054-050 50 tests
EUR 419.33
Description: Available in various conjugation types.

PE anti-human CD54

E16FHP054-100 100 Tests
EUR 629
Description: Available in various conjugation types.

Anti-Hu CD54 PerCP

PC-429-T025 25 tests
EUR 121

Anti-Hu CD54 PerCP

PC-429-T100 100 tests
EUR 242

Human CD54 ELISA Kit

M850540192 1 unit
EUR 791.27

Anti-Hu CD54 Biotin

1B-429-C025 0.025 mg
EUR 99

Anti-Hu CD54 Biotin

1B-429-C100 0.1 mg
EUR 198

APC anti-human CD54

E16FHA054-025 25 tests
EUR 416
Description: Available in various conjugation types.

APC anti-human CD54

E16FHA054-100 100 tests
EUR 1082.67
Description: Available in various conjugation types.

APC anti-mouse CD54

E16FMA054-025U 25 μg
EUR 325
Description: Available in various conjugation types.

Mouse Human CD54 (FITC)

E2790454 100ul
EUR 225
Description: Available in various conjugation types.

CD54 (PT0050) Mouse mAb

E2252714 100ul
EUR 225
Description: Available in various conjugation types.

Rat CD54 Antibody (RPE)

GWB-7FC364 100 TESTS Ask for price

FITC anti-mouse CD54

E16FMF054-050U 50 μg
EUR 303.33
Description: Available in various conjugation types.

Biotin anti-rat CD54

E16FRB054-100U 100 μg
EUR 563.33
Description: Available in various conjugation types.

FITC anti-human CD54

E16FHF054-025 25 tests
EUR 222.33
Description: Available in various conjugation types.

FITC anti-human CD54

E16FHF054-050 50 tests
EUR 317.67
Description: Available in various conjugation types.

FITC anti-human CD54

E16FHF054-100 100 Tests
EUR 496
Description: Available in various conjugation types.

CD54 (ICAM-1) Antibody

E2200350-F12 100ul
EUR 225
Description: Available in various conjugation types.

Rat CD54 Antibody (FITC)

GWB-2B0D75 0.5 mg Ask for price

CD54 ICAM-1 Antibody

GWB-918840 0.2 mg Ask for price

Rat CD54 Antibody (FITC)

GWB-C9392C 0.1 mg Ask for price

Anti-Ms CD54 Purified

11-625-C025 0.025 mg
EUR 44

Anti-Ms CD54 Purified

11-625-C100 0.1 mg
EUR 88

Anti-Hu CD54 Purified

11-228-C025 0.025 mg
EUR 71.5

Anti-Hu CD54 Purified

11-228-C100 0.1 mg
EUR 143

Anti-Hu CD54 Purified

11-229-C025 0.025 mg
EUR 71.5

Anti-Hu CD54 Purified

11-229-C100 0.1 mg
EUR 143

Biotin anti-human CD54

E16FHB054-100U 100 μg
EUR 758.33
Description: Available in various conjugation types.

Biotin anti-mouse CD54

E16FMB054-050U 50 μg
EUR 303.33
Description: Available in various conjugation types.

Rat CD54 Antibody (Biotin)

GWB-91B816 0.1 mg Ask for price

Purified anti-mouse CD54

E16FMU054-050U 50 μg
EUR 195
Description: Available in various conjugation types.

Purified anti-mouse CD54

E16FMU054-500U 500 μg
EUR 693.33
Description: Available in various conjugation types.

Purified anti-human CD54

E16FHU054-100U 100 μg
EUR 190.67
Description: Available in various conjugation types.

Purified anti-human CD54

E16FHU054-500U 500 μg
EUR 572
Description: Available in various conjugation types.

CD54 (pY512) Blocking Peptide

20-abx062763
  • Ask for price
  • Ask for price
  • 1 mg
  • 5 mg

CD54 Antibody (Low Endotoxin)

GWB-FBC46A 0.5 mg Ask for price

OADB00219-1MG - CD54 Antibody

OADB00219-1MG 1mg
EUR 959

OADB00223-2ML - CD54 Antibody

OADB00223-2ML 2mL
EUR 499

RECOMBINANT HUMAN CD54 Protein

GWB-Q00353 50 ug Ask for price

OASL01134-50UL - CD54 Antibody

OASL01134-50UL 50ul
EUR 269

OADB00217-200UL - CD54 Antibody

OADB00217-200UL 200uL
EUR 469

OADB00218-200UL - CD54 Antibody

OADB00218-200UL 200uL
EUR 469

OADB00220-100UG - CD54 Antibody

OADB00220-100UG 100ug
EUR 649

Mouse CD54 Antibody (PreservativeFree)

GWB-5D49C1 0.5 mg Ask for price

ICAM-1/CD54 Rabbit mAb

A19300 200μL
EUR 128.7
Description: A synthetic peptide corresponding to a sequence within amino acids 100-200 of human GPR109A/HM74A/HCAR2 (NP_808219.1).

ICAM-1/CD54 Rabbit mAb

A20216 100μL
EUR 323.7
Description: A synthetic peptide corresponding to a sequence within amino acids 593-692 of human Proprotein Convertase 9(PCSK9) (NP_777596.2).

ICAM-1/CD54 Rabbit mAb

A22198 500μL
EUR 83.2
Description: A synthetic peptide corresponding to a sequence within amino acids 227-326 of human CDK6 (Q00534).

CD54 (ICAM-1) Antibody (PE)

abx022366-100ug 100 ug
EUR 644.4

CD54 (ICAM-1) IHC Antibody

IW-PA1110 -
EUR 285

CD54 Antibody (PE / Cyanine 5)

abx228238-100g 100 µg
EUR 137.5

CD54 Antibody (PE / Cyanine 7)

abx228239-100g 100 µg
EUR 62.5
This case demonstrates for the primary time that an HCC affected person who’s proof against anti-PD-1 antibody immunotherapy can profit from anti-PD-L1 antibody immunotherapy, offering a probably promising technique for the therapy of HCC.

Leave a Reply

Your email address will not be published. Required fields are marked *

Related Post

Post-Vaccination Anti-SARS-CoV-2-Antibody Response in Patients with Multiple Myeloma Correlates with Low CD19+ B-Lymphocyte Count and Anti-CD38 Treatment

Post-Vaccination Anti-SARS-CoV-2-Antibody Response in Patients with Multiple Myeloma Correlates with Low CD19+ B-Lymphocyte Count and Anti-CD38 TreatmentPost-Vaccination Anti-SARS-CoV-2-Antibody Response in Patients with Multiple Myeloma Correlates with Low CD19+ B-Lymphocyte Count and Anti-CD38 Treatment

Few information can be found concerning the efficacy of anti-SARS-CoV-2 vaccines in sufferers with hematological malignancies, and specific, plasma cell neoplasia. This ongoing single-center examine aimed to explain the extent